ASCO 2016 Presentation: A Major Step Forward in the Immunotherapy of MSS Colorectal Cancer

To complete the trilogy of posts on the major new preliminary MSS Colorectal Cancer (CRC) immunotherapy results released today on the combination therapy of the MEK inhibitor cobimetinib + the PDL1 inhibitor atezolizumab, I’m excited to share the data released at ASCO-2016 this morning!  Both drugs are already FDA approved for other types of cancer – this was the first examination of their combined use against MSS-CRC.

When dosed alone, neither MEK inhibitors nor PD(L)1 inhibitors have shown significant published clinical activity against MSS-CRC.

As the first story of the trilogy (and I recommend you read this backdrop to today’s MAJOR “step forward” news story) – I previously wrote first about the abstract & science background as well as the patient impact of this study in my post ASCO 2016 PREVIEW: CHECKPOINT IMMUNOTHERAPY ACTIVITY IN MSS COLORECTAL CANCER.  I then wrote about the surprise development decision to skip the Phase 2 trial and go directly into a pivotal Phase 3 registration trial in the post THE FIRST PHASE 3 CHECKPOINT IMMUNOTHERAPY TRIAL FOR MSS COLORECTAL CANCER. That post also contains many Phase 3 trial recruitment details important to patients and caregivers who are interested in the trial.

After seeing the data released this morning at ASCO-2016, the developing company’s decision to move directly to a Phase 3 trial, although bold, is no longer surprising!

Due to potential copyright issues, I will not be including the actual slides in this post.  But they are floating all over Twitter – look at my Twitter feed (@CurrentIncurSci) and you will see the ones publicly floating around from multiple sources. They show a very compelling scientific and preliminary medical story!

Of note this is still just preliminary data in a small trial (23 patients).  But its signals are far enough away from known historical data that I think excitement of the therapy’s potential is very much warranted.  Obviously the developing company agrees – that is why they are skipping the Phase 2 trial to attempt to speed up potential FDA approval to the fastest timelines possible.

am2016-mobile-banner-text

Data Summary from today’s Abstract 3502 oral presentation: “Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC)”:

  • Historical monotherapy data: Neither cobimetinib nor pembrolizumab (a related PD-1 inhibitor) have previously shown significant response rates in MSS-CRC when dosed alone.
  • Combination Response Rate: 17% of patients had at least a 30% reduction in tumor size but including stable disease: ~40% of patients appeared to achieve clinical benefit. As long as it is durable, stable disease can sometimes be a very significant clinical benefit from immunotherapies not captured by traditional “response rate statistics” originally developed for chemotherapy drugs.
  • Durability: This was a key question going into the presentation this morning since it was not addressed by the written abstract released a few weeks ago. A number of patients responded for >1 year, including some that are still responding as of today’s talk’s data cutoff.  The response is durable in some patients. Because of the long term responders, a “median” (similar to an “average”) duration of overall survival response can not yet be calculated. 72% of patients were still alive at the 6-month mark. Keep in mind that these Phase 1 trials are usually tested in very late stage patients who have already exhausted many or all lines of approved therapies.
  • Individual patient responses i.e. the “spider plots”: Spider plots are line graphs that track individual patient responses to a drug over time. They are especially important in looking at immunotherapy responses because the “median is not the message” – there can be some very long term responders to some immunotherapies regardless of what the “average of patient responses” is.  Although the data is still being collected, the spider plot of MSS-CRC patients receiving this combination therapy visually looks similar to the spider plot of MSI-high CRC patients receiving a PD1-inhibitor monotherapy.  A scientific question to be answered: Does MEK inhibition with cobimetinib convert some MSS tumors into a “MSI-high-like” status?
  • KRAS-status: The trial was almost entirely KRAS-mutant patients, so it can not be said yet how the therapy behaves in KRAS-wildtype patients. This will be tested clinically in the randomized Phase 3 trial NCT02788279 which will include 50% KRAS-wildtype patients.
  • Preliminary comparison to current standard of care regorafenib: 6 month survival of this new immunotherapy combination was 72% with as I said a median still not calculable since it includes some patients who were still responding >1 year into the therapy. The median survival for patients who take regorafenib (current standard of care) is 6.4 months, so there appears to be potentially a positive step forward in this initial preliminary data.
  • Safety: Safety appeared to match know side effects of the drugs when they are used as single agents.
  • PDL1 Biomarker Expression: So far, there is no clear correlation between PDL1 expression and response to the therapy.
  • Getting even further into the scientific weeds: Cobimetinib alone increased CD8+ immune cell infiltration into the tumor as well as MCH I expression. This effect was enhanced using the combination therapy.  What this means: Cobimetinib both alone & in combination with atezolizumab appears to activate the immune system to recognize and infiltrate tumors in multiple MSS-CRC patients

Update added June 9, 2016: Here is the official ASCO post-meeting write up of the study presentation

In a Nutshell

I have to stress again that these results are preliminary from a small 23-patient study.  Sometimes small studies do not confirm in subsequent larger randomized studies.  Also: unique combination therapy toxicities may emerge as additional patients are dosed.

Of note: Some patients mistakenly equate immunotherapy drugs as having no toxicity or side effects.  This is not the case – these are powerful drugs interacting with the immune system and in some patients, significant side effects can occur.  Until a larger number of patients are tested, this experimental combo’s full safety & toxicity profile will not be known.

That being said… at the very least this study was a major scientific leap forward for the immunotherapy treatment potential of MSS CRC.  The clinical benefit response rate (including stable disease) was quite high for a “first step forward” (40%) and it appears to compare favorably with historical data of standard of care.  The pending randomized Phase 3 clinical trial will prove or disprove its preliminary signs of clinical activity as well as any potential superiority to current standard of care.

Repeating what I emphasized in the pre-ASCO post last week – the HUGE scientific impact of this preliminary clinical study is that IT SHOWS THAT YOU CAN SUCCESSFULLY TREAT AT LEAST SOME PATIENTS WITH MSS-CRC WITH IMMUNOTHERAPIES.

Period.

This is something I have openly strongly believed in and now there is clinical proof.

No matter how the final data shakes out in the randomized Phase 3 trial (response rates, durability etc) – that scientific statement is now both a fact and also incredibly important.  It is the “proof-of-principle” people have been searching for to open up more fully the immunotherapy research floodgates for MSS-CRC!

I am not a MD, so I can not give medical advice.  As a scientist & fellow patient, I do suggest that based upon today’s ASCO presentation, Stage IV MSS-CRC patients may want to consider printing out the ASCO abstract and discussing it with their MD(s) for medical advice in regards to the pending 42-site Phase 3 clinical trial.

Although the details of the preliminary clinical profile presented today need confirmation in the pending randomized Phase 3 clinical trial, this small preliminary study’s scientific impacts will be felt for years to come… So today is a day to CELEBRATE A SCIENTIFIC ADVANCE – a day of a significant scientific step forward, bringing us “one step closer” to the big eventual goal – a hoped for cure for “currently incurable” MSS-CRC.

PS: There was more promising info for both MSS and MSI-high CRC patients at ASCO this year – that will wait for a subsequent post…

18 Comments on “ASCO 2016 Presentation: A Major Step Forward in the Immunotherapy of MSS Colorectal Cancer

  1. Tom–Sorry if this is a dumb question, and I don’t mean to halt the progress of science, but… if both drugs are already FDA-approved, why wouldn’t a Stage IV patient simply request that his/her doctor prescribe them, rather than enroll in a clinical trial in which the patient has just 33% chance of getting both?

    Other than insurance, I guess. I mean, if you’re gambling with your life, wouldn’t you prefer a 40% chance of benefit over a 13% chance? (ie 33% times 40%)?

    This is not just idle curiosity as you might imagine. Any insight would be appreciated!

    Like

      • That is, of course, the right answer and I apologize for putting you on the spot by even asking the question. :-). Unfortunately I only thought of that *after* I hit “post comment”. Thinking before speaking has never been my strong point!

        Thanks for responding. Please enjoy your Sunday–you’re more than earned it!

        Like

    • Generally, your insurance company will not pay for off label use of FDA approved drugs. Atezo and Cobi are off label uses for colorectal cancer. There is an appeal process, but it takes a long time (months) and is rarely successful.

      Like

      • I’ve heard of at least one MSI-high CRC success story where she couldn’t travel to a PD-1 trial and her insurance company OK’d Keytruda off-label without even an appeal needed when her oncologist prescribed it for her. Just an anecdotal example (but I wasn’t actively searching for an example of this – she just happens to be a friend of mine) – I have no idea what percentage of the time these kind of prescriptions are approved.

        Like

  2. Just wanted to say… Congratulations! I’m so, so happy. I’m following atezo since it was MPDL3280A in 2012, and a dear fellow at the ColonClub was in it with bevacizumab. Later, I have been thrilled with our MSI-fellow S. responding to it, along with others. But when I read the abstracts days ago, and I saw this about MSS… just cried. When I read yesterday these news, all our threads about MPDL3280A (plus cobi http://coloncancersupport.colonclub.com/viewtopic.php?f=1&t=45485 ) came to mind…
    I thank to all the mates who went and go for clinical trials, who paved the way for these therapies to be mainstream.
    And thank you for being the voice for this : )
    All my love, keep well!!
    Maia
    (from the Colon Club)

    Liked by 1 person

    • Hi Maia – great to hear from you! It have been a while… 🙂 Thanks for your post here – yes the Colon Club (via your original post years ago) has been tracking this trial for a long time!.. I also got misty eyed when I saw the abstract come out myself. It is something the MSS community has been yearning for, for a long time………
      Take care!
      Tom

      Like

      • Take care, dearest Tom! I’m kind of back to following more close certain immunotherapies –to help a dear friend with metastatic bladder cancer, now.
        Always crap, cancer, but really really exciting times (atezo got approved 2 weeks ago for metastatic bladder cancer, after 30 years without now even a new chemo for the disease). Amazing, full of hope times!!
        Hang in there, friend! Love to the family 😀

        Liked by 1 person

  3. Pingback: ASCO 2016 PREZENTACE: ZÁSADNÍ KROK PRO IMUNOTERAPII U KOLOREKTÁLNÍHO KARCINOMU SE STABILNÍMI MIKROSATELITY (MSS-KRK) | Dobrodružství_terminálně_optimistického_života

  4. Pingback: Interview of a Colorectal Cancer Immunotherapy Breakthrough Principle Investigator | AdventuresInLivingTerminallyOptimistic

  5. Unfortunately my wife is on Stivarga which precludes here from the phase 3 trial. The Phase 1B looked very promising…Good LUCK!…Also, You may want to take a look at TAS-102 it stabilized her MSS-CRC for 9 months.

    Like

  6. Well Stivarga was basically useless, she returned to progression within 3 months. BUT although she cannot qualify for the Phase III due to her use of Stivarga her Oncologist has filed for compassionate care to be able to get cobimetinib (cobi) and atezolizumab paid for from her insurance company and a plead to the manufacture for the drugs. We’ve got our fingers crossed, If she is able to get it I will keep you posted with how well it works in real time. Good Luck and keep that CEA down!

    Like

    • hi Mike, I’m sorry to hear of her fast progression – please do keep us posted here by replying to this thread how the process works for you to obtain compassionate use exemptions for Cobi and Atezo, as an ex-Stivarga trial participant. This will be incredibly important important for other trial participants to see. Thank you and wishing all the best! -Tom

      Like

      • Well the fortunate news is that a Genetech was very helpful and agreed to donate Cobi and Atezo! The bad news is a very difficult discussion with the oncologist.
        She has been given the option of pursuing the use of the drugs or live life to the fullest with no potential additional side effect issues. My wife is currently an ECOG of 2 and she does not want to add anymore life restrictions for as long as she can. So she has chosen to not take the drugs. The problem with choosing the drugs at this point is you will live with additional side effects for likely little additional time. Virtually all reasonable related trials are not possible with her ECOG of 2. The concept is to manage the pain to the max extent possible without becoming too fatigued or being effected by many other potential side effects and live remaining life to the MAX! It all comes down to Quality of Life. He has given her 4-6 months and requested we see the recommended palliative care physician.

        Be aware that the oncologist has pointed out that there is some underlying info within the Phase 1 study, that questions the results. Seventy percent were of unknown microsatellite instability (MSI) status. MSI status was only presented for those that showed PR and 3 of those 4 were Asian resulting in a possible ethnic variable. Also, 17% (4) were taken off Cobi as of data cutoff. I notice it also does not address metastasis locations or tumor size details and the side effect percentages seem quite high. All this I’m sure will be addressed in the much larger Phase 3 study. However, I recommend investigation into this treatment and ask about the current ongoing trial if you are subject to progression under current treatment and qualify. This trial is at the top of the list for immunotherapy for those with MSI-CRC.

        Would I have taken Cobi and Atezo at the same point she is at? Easy to say I would but being in her position is the only way to know for sure what you would do.

        Following our discussions, we have become grateful. Upon the original diagnosis she was given a max of 3 years. She has gone through FOLFOX, FOLFIRI, TAS-102(Lonsurf) and Stivarga and now at a little over 3 1/2 years. We are very happy to have received the extra time and we have spent much of that time with little or no side effects and traveled and she has painted and together have done everything we’ve loved over 35 years of marriage.

        As a scientist myself in another realm, I also would like to put a little positive spin on this story by saying medical research is a fascinating science. It is very aggressive and just going back 3 years much has changed. With her peritonitis metastasis just 4 years ago the end of possible treatment would have happened much sooner. Good luck out there and enjoy life to the MAX!

        Like

  7. Pingback: Stability – Life Upstaged

  8. Pingback: A Potential MSS-CRC Immunotherapy from an AIDS Drug Start: the CCR5 Receptor Antagonist Maraviroc | AdventuresInLivingTerminallyOptimistic

  9. Pingback: MOŽNOSTI IMUNOTERAPIE KOLOREKTÁLNÍHO KARCINOMU SE STABILITOU MIKROSATELITŮ POMOCÍ LÉKU NA AIDS: ANTAGONISTA CCR5 RECEPTORU MARAVIROC | Dobrodružství_terminálně_optimistického_života

  10. Pingback: In Case of Emergency, Break Glass | AdventuresInLivingTerminallyOptimistic

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Avonturen_in_het_ongeneeslijk_optimistisch_leven

Scroll naar beneden langs de grote bomen:-)

My Cancered Life

Relentlessly Attacking Cancer Through Fitness, Family, Advocacy, and Laughter

Dobrodružství_terminálně_optimistického_života

Přejděte dolů kolem velkých stromů :-)

Aventuras_Viviendo_Terminalmente_y_Optimistamente

Más allá de los grandes árboles :-)

乐观地和绝症一起进行人生冒险

向下拖动滚动条看看大树底下 :-)

Приключения_безнадежного_оптимиста

Пролистайте вниз мимо больших деревьев :-)

Cancer Riot

Scroll Down Past the Big Trees :-)

SugarCone Biotech

Research and Development - Analysis, Consulting, Investment

Fightin 4 Blue.org

Colorectal Cancer Awareness

Tami Boehmer | Miracle Survivors

Just another WordPress.com site

Adventures in Spiritual Living

Riding the spiritual waves of everyday life

life and breath: outliving lung cancer

for the terminally optimistic

%d bloggers like this: